Lilly and ParAllele to Launch Affy-based Drug-Metabolism Genotyping Assay in August or September | GenomeWeb

NEW YORK, March 17 (GenomeWeb News) - Eli Lilly and ParAllele plan to enable contract research organizations to use their joint genotyping assay in August or September, a Lilly official told Pharmacogenomics Reporter, GenomeWeb News' sister publication, this week.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.